Further, they highlight that the effect of PARP inhibitors on ovarian cancer is probably not affected by FIGO stage status, response to first-line chemotherapy, and residual macroscopic disease after debulking surgery. The gene discussed is PARP1; the disease is ovarian carcinoma.